Comparative Pharmacology
Head-to-head clinical analysis: EXALGO versus NUCYNTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXALGO versus NUCYNTA.
EXALGO vs NUCYNTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Category C
Category C
Opioid Analgesic
Opioid Analgesic